MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or Lymphoma

MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or Lymphoma

Advanced Stage Solid Tumors

Terminated

1

Start Date 07/01/2007

Age of Trial (yrs) 16.9

Gleevec-resistant

KIT/PDGFRA inhibitor

Block KIT

GIST not specified. GIST patient enrollment unknown.

CDR000055652, SUPERGEN-SGI-0470-01, VPCCS-SGI-0470-01

SuperGen

TGen Clinical Research Services Cancer Care Coordinator

480-323-1255

Oral

This drug is manufactured by SuperGen Pharmaceuticals. A phase I trial opened in July of 2007. MP-470 is a tyrosine kinase inhibitor of KIT (including forms of mutated KIT), PDGFR, c-Met, c-RET and AXL. MP-470 may inhibit some of the secondary mutations that cause resistance to Gleevec. In addition, AXL may be activated in some GISTs and inhibition of AXL may be beneficial to some GIST patients.
MP470 inhibits the PDGFRA D842V mutation (in exon 18) in test tube experiments.
Note:
Unlike some of the other kinase inhibitors that inhibit multiple targets, MP-470 does not inhibit the VEGF receptors.

Study chairs or principal investigators
Gregory Berk, MD, Study Chair, SuperGen

This trial listing seems to have been replaced by NCT00894894.